Why the WSJ piece ‘Legal Marijuana’s Disastrous Legacy’ missed the mark

BAD REPORTING
Why the WSJ piece ‘Legal Marijuana’s Disastrous Legacy’ missed the mark

Driving the news: Earlier this month, the Wall Street Journal — I should say, a newspaper that I admire and many friends work for or have worked for in the past — published an op-ed on cannabis legalization that missed the mark, for many reasons.

The piece claims that legalizing cannabis has been an abject disaster, and urges President Trump to stop federal cannabis reform in its tracks.

Here’s my response as the editor-in-chief of Cultivated Media and an advocate for truthful reporting.

Let’s dive in: The argument in the op-ed boils down to, "legal weed causes disorder," which both the writer, Charles Lehman, and his organization, the right-wing Manhattan Institute, have been pushing on social media and in other outlets. 

It's not a strong argument. It's polemic. 

The first study linked in the piece — in which much of the research is cherry-picked — shows the opposite of the author's claims: It found no significant association between cannabis use disorder and legalization. And other experts have said the definition of cannabis use disorder, which Lehman relies on to illustrate the evils of legalization, is too broad to be a useful diagnosis.

In fact, the vast majority of researchers say more studies are needed to generate useful conclusions about many of the claims in the piece, and that changes seen in traffic accidents, hospital admissions, and homelessness pre- and post- legalization may have more to do with increased population or other policy shifts rather than legalization itself.

Many of Lehman’s other claims don't meet scrutiny as well. While it is true that legalization has not killed the illicit market, much of that is because of:

• Federal bans on interstate commerce — cannabis can't cross state lines so supply/demand is usually misaligned within states, leading to product diversion and wholesale price fluctuations which are difficult for operators to manage their balance sheets against. 

• Early policy mistakes with respect to startup costs, taxes, access to capital, and the lack of enforcement on illicit operators. 

The sky hasn’t fallen in Canada

It's also important to note that we do have a clear example of federally coherent cannabis policy in Canada, which legalized in 2018. While the industry is still a work in progress for many companies and consumers, the sky has not fallen. 

The vast majority of people who walk around downtown Toronto or midtown Manhattan — places that writers like Lehman or Alex Berenson maintain are filled with crime and disorder spurred by legalization — aren’t thinking about cannabis at all, unless they’re specifically seeking it out or happen to pass by a dispensary. 

What also goes unsaid in the WSJ piece are the clear benefits of legalization, including capturing tax revenue from criminal organizations, fixing the sordid history of racialized policing, and creating economic opportunities for communities, often minorities or in low-income zip codes, that were punished for cannabis in the first place. 

Legalization also means consumer safety: While the testing infrastructure for pesticides, yeast, and heavy metals in cannabis products certainly isn’t perfect, as we’ve covered in this newsletter, consumers at least know how much THC they’re ingesting because legal products are labeled. They’re able to choose lower doses or higher doses based on their needs, and not rely on what’s handed to them in a Ziploc bag. 

All this is to say why researchers, unlike opinion writers, don’t work backwards from pre-ordained conclusions. Because once you do, you can bend evidence to fit your hypothesis neatly. 

As it turns out, the reality of social science, like the humans it studies, is messy. Those who claim to see things in black-and-white, writers like Lehman or Berenson, are often pushing an agenda. 

The bottom line: It’s not my view that legalization is a panacea to fix society’s ills. But it won’t cause them either. 

In fact, outside of what we as cannabis nerds discuss daily in this newsletter, the impact of legalization on those who don’t buy, sell, or consume cannabis is minimal at best, as much research has shown.  

As with any policy shift, allowing commercial cannabis sales, of course, has costs and benefits. 

Using the policy levers regulators have available via licensing structures, taxation, and more to capture the benefits of legalization while ameliorating the real social costs is the core challenge. 

States are truly a laboratory of democracy, and luckily we now have over a decade of data to work from to move cannabis policy in a better direction for consumers, for the industry, and for the general public. 

-JB

“This administration made a commitment to Kentuckians suffering from cancer, PTSD, multiple sclerosis and other eligible conditions, and I am proud we are making progress to deliver safe, affordable access to medical cannabis,” Kentucky Gov. Andy Beshear said. 

“Through work with the General Assembly to move up business licensing by six full months and providing licensees with the tools they need to get up and running, we are closer than ever to providing Kentuckians with life-changing relief.” 

Armory Kentucky officially became the state’s first medical cannabis cultivator when it commenced operations last Friday. Additional openings are expected in coming weeks, and with the start of cultivation, retail could conceivably launch by the end of the year in the Bluegrass State.

Florida cannabis market slows down 📉

Florida’s cannabis market is slowing down, per statistics from Florida's Office of Medical Marijuana Use (OMMU). As of May 2025, annual patient growth had fallen to 3.4% from 8.4% the year before, and total sales have decreased. Since Florida failed to pass legalization in November, the biggest cannabis companies operating in Florida, Ayr Wellness, Curaleaf, Trulieve, and Verano, are down 94.77%, 80.29%, 63.7% and 88.23% respectively. New Cannabis Ventures has more. 

New York recalls pesticide-laden pot ☠️

The New York Office of Cannabis Management issued a recall on July 14 of multiple products from East End Flower Farm. The products, all cannabis flower, exceeded testing limits for pesticides. The products were already quarantined because after being tested by Lexachrom Analytical Laboratory, which is no longer permitted to test cannabis in the state. The pesticides were identified after the suspect products were retested by a different lab.  

NJ approves its first four consumption lounges 💨

New Jersey's Cannabis Regulatory Commission unanimously approved four applications from existing retailers for a consumption area endorsement, during its July 15 meeting. That endorsement allows retailers to allow the general public to consume cannabis onsite. All retailers are eligible to apply for the endorsement, assuming they can produce an acceptable site plan and get approval from their city or town.

HAVE YOUR VOICE HEARD
Are you getting the banking support your business needs?

Whether you're satisfied or frustrated, we want to hear from you.

Shield Compliance, a leading cannabis banking compliance provider, is conducting a survey of licensed cannabis operators about their satisfaction with the banking products and services available to them.

Take the survey.

Your responses will help shape how banks and credit unions serve licensed cannabis businesses — like yours — by delivering better products and services.

The survey takes just a few minutes to complete.

You can remain anonymous or enter to win one of several $250 Amazon gift cards by sharing your contact info at the end.

Thank you for participating.

Jay and Jeremy caught up with Distru CEO Blaine Hatab last week, where they discussed his entrepreneurial journey, and how AI is set to disrupt the industry. 

Check it out — and be sure to subscribe to our Youtube channel:

Marijuana Policy Project hires new executive director 🤝

Marijuana Policy Project, the largest American cannabis advocacy group, said Adam J. Smith would be its new executive director. Smith brings over 30 years of experience in the drug reform movement, which the organization hopes to take advantage of. Read more.

San Diego scientists try to unlock the secrets of cannabis | KPBS 65

Whose Role Is It Anyway: Why the State Needs to Lead on Closing Unlicensed Cannabis Shops | Law.com